Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 11;17:100371. doi: 10.1016/j.lanepe.2022.100371

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 2 — Time course of anti-SARS-CoV-2 IgG (A/C) or receptor binding domain (B/D) antibodies in seroconverted Dia-Vacc study participants. Figure 2A: IgG against S1 protein in different study groups. Each thin line corresponds the anti-Spike S1 protein IgG antibody values (QuantiVac, Euroimmun) of a study participant from T0 (vaccination start) via T2 (eight weeks after vaccination start) to T3 (six months after vaccination start). Only patients with successful de novo seroconversion at T2 (IgA or IgG antibody positivity against the SARS-CoV-2 S1 protein) after 2x mRNA vaccination and without SARS-CoV-2 nucleocapsid (NCP) antibodies were considered. All three patient groups are represented (MP-green, DP-red, KTR-blue). The area shaded grey designates IgG range below positivity level. The vertical axis is depicted on $lo g_{10}$ scale with corresponding unit BAU/ml. Figure 2B: Receptor binding domain antibodies against S1 protein in different study groups. Each thin line corresponds the anti-Spike S1 protein RBD-IgG antibody values (Euroimmun) of a study participant from T2 (eight weeks after vaccination start) to T3 (six months after vaccination start). Only patients with successful de novo seroconversion at T2 (IgA or IgG antibody positivity against the SARS-CoV-2 S1 protein) after 2x mRNA vaccination and without SARS-CoV-2 nucleocapsid (NCP) antibodies were considered. All three patient groups are represented (MP-green, DP-red, KTR-blue). The area shaded grey designates IgG range below positivity level. The vertical axis is depicted on $lo g_{10}$ scale with corresponding unit % inhibition. Figure 2C: IgG against S1 protein dependent on vaccine type. Each thin line corresponds the anti-Spike S1 protein IgG antibody values (QuantiVac, Euroimmun) of a study participant from T0 (vaccination start) via T2 (eight weeks after vaccination start) to T3 (six months after vaccination start). The thicker lines represent average responses by vaccine type (red-BNT162b2mRNA and blue 1273-mRNA) in each group. Only patients with successful de novo seroconversion at T2 (IgA or IgG antibody positivity against the SARS-CoV-2 S1 protein) after 2x mRNA vaccination and without SARS-CoV-2 nucleocapsid (NCP) antibodies were considered. The area shaded grey designates IgG range below positivity level. The vertical axis is depicted on $lo g_{10}$ scale with corresponding unit BAU/ml. Figure 2D: Receptor binding domain antibody against S1 protein dependent on vaccine type. Each thin line corresponds the anti-Spike S1 protein RBD-IgG antibody values (Euroimmun) of a study participant from T0 (vaccination start) via T2 (eight weeks after vaccination start) to T3 (six months after vaccination start). The thicker lines represent average responses by vaccine type (red-BNT162b2mRNA and blue 1273-mRNA) in each group. Only patients with successful de novo seroconversion at T2 (IgA or IgG antibody positivity against the SARS-CoV-2 S1 protein) after 2x mRNA vaccination and without SARS-CoV-2 nucleocapsid (NCP) antibodies were considered. The area shaded grey designates IgG range below positivity level. The vertical axis is depicted on $lo g_{10}$ scale with corresponding unit % inhibition.